Equity Profile

TEVA

Teva Pharmaceutical Industries Limited

Health CarePharmaceuticals$37.5B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Teva Pharmaceutical Industries Limited is a global leader in the pharmaceutical sector, focusing on generic and specialty medications. With a market cap of $37 billion, Teva plays a critical role in providing affordable healthcare solutions, especially in a time when healthcare costs are a major concern for consumers and governments alike.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1-2026, Teva reported an EPS of $0.53, exceeding expectations by nearly 9%. The stock reacted positively, gaining almost 12% the following day.

Management Promises & Guidance

Continued focus on expanding its generic drug portfolio.
Commitment to cost-cutting measures to improve margins.
Investments in research and development for specialty medications.

Expectations

Wall Street Expectations

Overall, analysts are cautiously optimistic about Teva's upcoming earnings, given its recent performance and historical ability to beat EPS estimates.

Bull Case

If Teva continues its trend of beating EPS estimates, it could signal strong operational efficiency and market demand, leading to further stock appreciation.

Bear Case

Conversely, any signs of declining revenue or increased competition in the generics market could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Teva's history of beating EPS estimates, this number will be critical in determining market sentiment post-earnings.

What is the outlook for revenue growth in the generics segment?

Revenue growth in generics is essential for Teva's future profitability, and any decline could raise concerns among investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Teva's ability to maintain its competitive edge in the generics market, especially given its recent operational improvements.

Supporting Evidence

Teva has consistently beaten EPS estimates, indicating strong management performance.

Options pricing suggests a lower expected move compared to historical averages, indicating potential upside.

The company's focus on cost-cutting and R&D investments may not be fully reflected in current market sentiment.

Key Risk

If generics revenue growth exceeds expectations, it could significantly alter the market's perception of Teva's future prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Teva's ability to maintain or improve its earnings amidst competitive pressures in the pharmaceutical industry.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.50 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a potential move of about 5.66%, indicating some uncertainty around the earnings report.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests the stock could rise by about 3.79% on the following day, reinforcing investor confidence.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further commentary from management.

Miss

A miss could lead to a decline of around 3.79%, as investors reassess the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on cost-cutting initiatives and their impact on margins.
2Details on the performance of key generic drugs in the market.
3Management's outlook on competitive pressures in the generics sector.
4Insights into R&D progress for specialty medications.
5Any commentary on future guidance for revenue growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1-2026, Teva reported an EPS of $0.53, exceeding expectations by nearly 9%. The stock reacted positively, gaining almost 12% the following day.

Management Promises & Guidance

Continued focus on expanding its generic drug portfolio.
Commitment to cost-cutting measures to improve margins.
Investments in research and development for specialty medications.

Expectations

Wall Street Expectations

Overall, analysts are cautiously optimistic about Teva's upcoming earnings, given its recent performance and historical ability to beat EPS estimates.

Bull Case

If Teva continues its trend of beating EPS estimates, it could signal strong operational efficiency and market demand, leading to further stock appreciation.

Bear Case

Conversely, any signs of declining revenue or increased competition in the generics market could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Teva's history of beating EPS estimates, this number will be critical in determining market sentiment post-earnings.

What is the outlook for revenue growth in the generics segment?

Revenue growth in generics is essential for Teva's future profitability, and any decline could raise concerns among investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Teva's ability to maintain its competitive edge in the generics market, especially given its recent operational improvements.

Supporting Evidence

Teva has consistently beaten EPS estimates, indicating strong management performance.

Options pricing suggests a lower expected move compared to historical averages, indicating potential upside.

The company's focus on cost-cutting and R&D investments may not be fully reflected in current market sentiment.

Key Risk

If generics revenue growth exceeds expectations, it could significantly alter the market's perception of Teva's future prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Teva's ability to maintain or improve its earnings amidst competitive pressures in the pharmaceutical industry.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.50 would support the bear case, raising concerns about profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a potential move of about 5.66%, indicating some uncertainty around the earnings report.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests the stock could rise by about 3.79% on the following day, reinforcing investor confidence.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further commentary from management.

Miss

A miss could lead to a decline of around 3.79%, as investors reassess the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on cost-cutting initiatives and their impact on margins.
2Details on the performance of key generic drugs in the market.
3Management's outlook on competitive pressures in the generics sector.
4Insights into R&D progress for specialty medications.
5Any commentary on future guidance for revenue growth.